NIDDK - COVID-19 Supplement for DFU Clinical Research Unit

Supplement Application for COVID-19 Research in Diabetes Patients

Drs. Rodica Pop-Busui, Eva Feldman, Salim Hayek, Matthias Kretzler, and Subramaniam Pennathur were jointly awarded a National Institute of Diabetes and Digestive & Kidney Diseases (NIDDK) in October 2020 to fund research of the effect of COVID-19 on diabetes patients. Individuals with diabetes, particularly those with type 2 diabetes (T2D), are highly susceptible to COVID-19-induced adverse outcomes and complications. The massive global T2D burden and high number of COVID-19 infections is creating large and significantly vulnerable COVID-19 T2D patient populations. In addition, the impact of severe COVID-19 infection on the risk of new onset and/or progression of preexisting kidney, cardiovascular, and neurological complications it is not known. This research will establish the knowledge base needed to generate urgently required and immediately applicable clinical guidelines for managing current and future COVID-19 T2D patients in light of their particular vulnerability.